Senti Biosciences, Inc. announced that it will issue 6,600,000 common shares at a price of $10 per share for gross proceeds of $66,000,000 on December 20, 2021. The transaction included participation from institutional investors including funds and accounts managed by Morgan Stanley Institutional Fund, Inc. - Counterpoint Global Portfolio, a fund managed by Morgan Stanley Investment Management Inc., The Invus Group, LLC, Parker Institute for Cancer Immunotherapy, funds and accounts advised by T. Rowe Price Group, Inc., returning investors, Eight Partners VC, LLC, Amgen Ventures, LifeForce Capital, New Enterprise Associates, Inc. and other investors. The transaction has been approved by the board of directors.

The transaction is expected to be completed in the second quarter of 2022, subject to approval by Dynamics Special Purpose Corp. and the company's shareholders and satisfaction, or the waiver of, customary closing conditions identified in the business combination agreement.